این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Research in Pharmaceutical Sciences، جلد ۱۹، شماره ۶، صفحات ۶۵۶-۶۶۸
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Ultra-small phospholipid nanoparticles in the treatment of combined hyperlipidemia: a randomized placebo-controlled clinical trial
چکیده انگلیسی مقاله Background and purpose: Combined hyperlipidemia is associated with an increased risk of cardiovascular events. This clinical trial investigated phospholipovit (essential phospholipids, Institute of Biomedical Chemistry, Moscow, Russia), an ultra-small phospholipid nanoparticle (micelles), targeted to phospholipids of HDL in lowering non-HDL-cholesterol (non-HDL-C) and triglycerides (TG) levels in patients with combined hyperlipidemia and moderate cardiovascular risk. Experimental approach: A randomized, double-blinded, placebo-controlled phase II trial was conducted on 100 patients. Phospholipovit or placebo was randomly administered orally (500 mg) 2 times a day for 12 weeks. The primary endpoint was the percent change of non-HDL-C from baseline to 12 weeks of exposure. Findings/Results: Treatment with phospholipovit resulted in a mean non-HDL-C reduction of 13.2% versus 4.3% compared with placebo. The absolute decrease in non-HDL-C was -23.2 (-48.7 - 7.0) mg/dL versus -7.3 (-17.0 - 12.0) mg/dL, significantly. The therapeutic target of non-HDL-C less than 130 mg/dL (3.4 mmol) was achieved in 15 of 39 patients (38.5%) in the phospholipovit group versus 2 of 41 patients (4.9%) in the placebo group OR 11.8 (2.4 - 116). Significant reduction in TG, apolipoprotein B, total cholesterol, and very low-density lipoprotein cholesterol levels was also observed. There were no changes in the liver and kidney functions, vital signs, or electrocardiography. There were no serious adverse events. Conclusion and implications: Phospholipovit significantly reduced non-HDL-C, TG, and atherogenic lipoproteins in patients with combined hyperlipidemia and moderate cardiovascular risk. It can be used as an add-on therapy to statins.    
کلیدواژه‌های انگلیسی مقاله Combined hyperlipidemia,Non-HDL-C,Phospholipid nanoparticles (micelles),TG.
نویسندگان مقاله | Alexander Archakov
National Medical Research Center of Cardiology named after Academician E.I. Chazov, Moscow, Russia.


| Valery Kukharchuk
Institute of Biomedical Chemistry, Moscow, Russia.


| Andrey Lisitsa
Institute of Biomedical Chemistry, Moscow, Russia.


| Elena Ponomarenko
Institute of Biomedical Chemistry, Moscow, Russia.


| Yulia Romashova
Institute of Biomedical Chemistry, Moscow, Russia.


| Tatiana Pleshakova
Department of Probability Theory, Faculty of Mechanics and Mathematics, Lomonosov Moscow State University, Moscow, Russia.


| Elena Yarovaya
Department of Probability Theory, Faculty of Mechanics and Mathematics, Lomonosov Moscow State University, Moscow, Russia.


| Vladimir Kutsenko
Institute of Biomedical Chemistry, Moscow, Russia.


| Maria Guseva
Institute of Biomedical Chemistry, Moscow, Russia.


| Valery Beregovykh
Institute of Biomedical Chemistry, Moscow, Russia.


| Olga Ipatova
National Medical Research Center of Cardiology named after Academician E.I. Chazov, Moscow, Russia.


| Marina Zubareva
Institute of Biomedical Chemistry, Moscow, Russia.


| Elena Tikhonova
Institute of Biomedical Chemistry, Moscow, Russia.


| Sergei Ivanov
Institute of Biomedical Chemistry, Moscow, Russia.


| Farid Bedretdinov
Institute of Biomedical Chemistry, Moscow, Russia.


| Sergey Markin


نشانی اینترنتی http://rps.mui.ac.ir/index.php/jrps/article/view/2279
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده Original Article
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات